View Clinical Trial (Medical Research Study)

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis - NCT00987467-21287(Clinical Trial 353232)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Baltimore
State:  
MD
Zip Code: 21287
Conditions: Atopic Keratoconjunctivitis
Purpose: Atopic keratoconjunctivitis (AKC) is a rare type of ocular allergy that is often associated with eczema. Over time, the complications from this disease process lead to loss of vision due to continual scarring of the corneal surface. The pathophysiology of AKC has not been fully elucidated, and the triggers are still unknown. Corticosteroids are very effective in controlling the acute symptoms of AKC. However, two thirds of patients managed with a combination of oral antihistamine, topical mast cell stabilizer, and intermittent topical steroid regimen eventually developed significant keratopathy and vision loss. Additionally, there are many side effects of corticosteroids, including local immunosuppression, cataract formation, and increased risk of glaucoma. Cyclosporin A is an immunomodulator that specifically inhibits T lymphocytes by blocking the expression of the interleukin-2 receptor. It also blocks the release of inflammatory mediators from mast cells and eosinophils. Cyclosporin has no known side effects except for burning upon instillation, and safe to use over long-term . The investigators have demonstrated that a 0.05% ophthalmic emulsion of cyclosporine has been shown to be effective at improving the ocular signs and symptoms of AKC over short-term. However, the long-term efficacy of cyclosporine A in slowing the natural history of AKC and possible steroid sparing effects have not been assessed. The investigators hypothesize that cyclosporine A can be used as a mainstay treatment of AKC to control signs and symptoms over a long period of time and also prevent the progression of this disease.
Study summary:
Criteria: Inclusion Criteria: - Patient has known diagnosis of atopic keratoconjunctivitis - Patient has been on cyclosporine 0.05% eye drops for control of atopic keratoconjunctivitis - Patient has been followed up for at least for 1 year - Patient is able to give informed consent - Patient is able to tolerate a full ophthalmic exam Exclusion Criteria: - Patient has any other diagnosis (i.c. vernal keratoconjuntivitis, giant papillary conjunctivitis) that may alter the clinical appearance or behavior of their ocular surface)
Study is available at: Johns Hopkins Hospital - Wilmer Eye Institute
Baltimore, MD 21287
United States

Primary Contact:
Esen K Akpek, MD
Phone: 410-955-7927

Secondary Contact:
Esen K Akpek, MD
Email: esakpek@jhmi.edu
Phone: (410) 955 7927
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.